Medivation, Inc. – $MDVN – Confident Investor Rating: Poor

Company name Medivation, Inc.
Stock ticker MDVN
Live stock price [stckqut]MDVN[/stckqut]
Confident Investor Rating Poor

The following company description is from Google Finance: http://www.google.com/finance?q=mdvn

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases, for which there are limited treatment options. Its product candidates in clinical development are MDV3100, which is in Phase 3 development for the treatment of advanced prostate cancer, and dimebon (latrepirdine), which is in Phase 3 development for the treatment of Alzheimer´┐Żs disease and Huntington disease. Its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas, and its dimebon program is partnered with Pfizer Inc. (Pfizer).

Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in this stock. It is not possible to confidently invest in a company that is not currently profitable.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.